NCT00135967View on ClinicalTrials.gov

Mycophenolate Mofetil in Membranous Nephropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2002

Conditions
Glomerulonephritis, Membranous
Interventions
DRUG

mycophenolate mofetil orally 1000 mg twice a day (BID)

DRUG

prednisone 0,5 mg/kg orally on alternate days

DRUG

intravenous (i.v.) methylprednisolone 1000 mg, total 9

Trial Locations (1)

6500 HB

Department of Nephrology Radboud University Nijmegen Medical Centre, Nijmegen

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT00135967 - Mycophenolate Mofetil in Membranous Nephropathy | Biotech Hunter | Biotech Hunter